Abstract
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A nnual influenza epidemics due to influenza A and B viruses remain a substantial cause of morbidity and mortality worldwide. Epidemics particularly affect vulnerable years, and people with chronic medical conditions. 1-3 Each year, 3-5 million cases of severe illness and these epidemics worldwide. Among the many among humans. 4 In Indonesia, few influenza surveillance studies have been published. A study on the epidemiology of influenza in municipality, district of and district of was conducted on infected by influenza viruses. 5 In addition, a study by in Riyadh, Saudi Arabia on Indonesian Muslims on positive viral culture were positive for influenza B, and 6 standard formulation for influenza prevention. Because one or more new, antigenically-drifted variants circulate annually, vaccines must be updated to provide optimal protection against the predicted prevalent strains for the next influenza season.
provide annual guidance for strain selection based on new drift variants detected through a global influenza The current global, seasonal
Europe, North America, Australia and Japan. In the event of a pandemic, even if all producers switch to the production of a pandemic influenza vaccine, production population. Influenza vaccine production expansion is an urgent measure in preventing widespread disease.
producer in Southeast Asia, including Indonesia. Ultimately, countries in this region may not have the vaccine if a pandemic occurs. Establishment of an influenza vaccine production facility is vital to cover the facilitating the technology transfer needed to formulate and manufacture the influenza vaccine locally. The aim of this trial was to assess the antigenicity and safety of ® after a single dose.
Methods

Study Design and Population
We conducted an experimental, randomized, singlewritten, informed consent. We excluded subjects who:
had history of uncontrolled coagulopathy or blood had received treatment which altered their immune response (e.g., intravenous immunoglobulin or other might interfere with the assessment of the trial especially with infectious diseases or fever (axillary Prior to this study, approval was obtained and local regulatory requirements.
Antigenic characterization and serology
in the deltoid muscle of the left arm in each subject. Blood specimens were obtained before separation, specimens were blinded and frozen, until tested. Immunogenicity was assessed using Laboratory, Bandung. A standardized test was used to assess antibody response to influenza antigens.
mixtures. Titer was defined as the highest dilution of 13
Reactogenicity and safety
After vaccine injection, participants were observed for temperature was also measured. Participants received memory aids to record the severity of injection site reactions, reactogenicity events, and general adverse were provided with the memory aids. Participants reported immediate reactogenicity symptoms within reported by the participants using standardized diaries this period, each participant recorded the appearance, systemic reactions. The intensity of local reactions was assessed using a plastic bangle. 14
Vaccines
The current inactivated, trivalent influenza vaccine the year. Because of the frequent emergence of new influenza variant strains, the antigenic composition of influenza vaccines needs to be evaluated yearly, and the trivalent inactivated influenza vaccines are .
Results
study. The antibody titers of two participants were not assessed as they did not provide complete blood specimens. The characteristics of subjects are shown in Table 1 All vaccines were well-tolerated. There were who reported systemic events, most frequently fatigue (Table 2 ) There were no serious adverse events reported during the study. safe when administered to adolescents and adults. The immunogenic parameters we assessed were the percentage of subjects with anti-influenza titers with a 4 times increase in antibody titer, and the percentage of subjects transitioning from seronegative to seropositive. 15 The percentages of subjects with The GMT after percentages of seronegative subjects who transitioned
The GMT after of seronegative subjects transitioning to seropositive
In this study, all vaccines were well-tolerated.
There were no serious adverse events reported during the study. The reactogenicity events reported were consistent with those commonly reported with systemic reactions. All vaccines were well-tolerated and no serious adverse events occurred during their study.
et al. concluded that the reactogenicity events were significant in the TIV versus placebo group. Events observed were injection site pain, injection site redness and swelling, myalgias, arthralgias, severity. There was a slightly higher incidence of spontaneous AEs in the TIV versus placebo group primarily due to the persistence of injection site pain and redness. Overall, the results suggest that the safety profile of TIV was acceptable and consistent with the historical performance of similar products. In placebo-controlled, blinded studies, the most frequent side-effect of vaccination is soreness at the vaccination to two days following administration of influenza vaccine.
These reactions are generally mild and transient, resolving spontaneously within two to three general discomfort and muscle pain can affect those individuals without previous exposure to the antigens These reactions may
Limitations of this study were the small sample age.
In conclusion, our results support the use of for adolescents and adults. The vaccine was immunogenic and safe showed no adverse effects. II. Adverse reactions in children and adults. Am J Epidemiol. .
